Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response

Abstract

The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.

1 . Use of a recombinant LAG-3 protein or derivative thereof that elicits a monocyte-mediated immune response, for the manufacture of a medicament inducing an increase in the number of monocytes for the treatment of an infectious disease or cancer. 
     
     
         2 . Use according to  claim 1 , wherein the medicament consists of an effective plurality of doses of a recombinant LAG-3 protein or derivative thereof. 
     
     
         3 . Use according to  claim 2 , wherein said plurality of doses of a recombinant LAG-3 protein or derivative thereof is formulated so as to allow administration of one dose every one to several weeks for at least 12 weeks, and preferably for at least 24 weeks, separated by 13-day ±2 days administration-free intervals. 
     
     
         4 . Use according to either one of  claims 2 or 3 , wherein said one dose of a recombinant LAG-3 protein or derivative thereof is formulated so as to allow subcutaneous or intravenous administration in the range of 0.25-30 mg, and preferably 6-30 mg, of a recombinant LAG-3 protein or derivative thereof to a patient in need thereof having a body mass index (weight/height 2 ) in the range of 18-30 kg/m 2 . 
     
     
         5 . Use according to any one of  claims 2 to 4 , wherein said doses of a recombinant LAG-3 protein or derivative thereof are formulated so as to allow administration with a compound having anti-cancer or anti-infectious disease immunotherapeutical or chemotherapeutical properties. 
     
     
         6 . Use according to  claim 5 , wherein one dose of a recombinant LAG-3 protein or derivative thereof comprises 0.25-30 mg, and preferably 6-30 mg, of said recombinant LAG-3 protein or derivative thereof. 
     
     
         7 . Use according to either one of  claims 5 or 6 , wherein said compound is selected from the group consisting of chemotherapy agents. 
     
     
         8 . Use according to  claim 7 , wherein said chemotherapy agents are selected from the group consisting of taxanes, for example paclitaxel and docetaxel, and anthracyclines, for example doxorubicine, and gemcitabine. 
     
     
         9 . Use according to either one of  claim 5 or 6 , wherein said compound is selected from the group consisting of therapeutic antibodies killing tumour cells through ADCC (antibody-dependent cell-mediated cytotoxicity), and mixtures thereof. 
     
     
         10 . Use according to  claim 9 , wherein said therapeutic antibodies are from the group consisting of rituximab, cetuximab, edrecolomab and trastuzumab. 
     
     
         11 . Kit-of-parts containing recombinant LAG-3 protein or derivative thereof and a therapeutic antibody as mentioned in  claims 9 or 10 , for simultaneous, separate or sequential use. 
     
     
         12 . Kit-of-parts containing recombinant LAG-3 protein or derivative thereof and a compound having anti-cancer chemotherapeutical properties as mentioned in  claims 7 or 8 , for simultaneous, separate or sequential use.